Dean Fennell, MBBS, PhD, FRCP is a Professor and consultant in Thoracic Medical Oncology, and Director of the Leicester Mesothelioma Program at the University Hospitals of Leicester, UK.
Prof. Fennell initially qualified in Pharmacology followed by Medicine and Surgery from University College London, UK. After completing medical training at UCL, Hammersmith, Brompton, Guy’s and St Thomas’ Hospitals in London, he obtained Membership of the Royal College of Physicians. He then completed his PhD in Oncology as a MRC Clinical research fellow in UCL. He completed training in Medical Oncology at St Bartholomew’s Hospital, and then undertook several Cancer Research UK Clinician Scientist Fellowships.
Prof. Fennell is member of the International Association for the Study of Lung Cancer (IASLC) mesothelioma taskforce, is a past president of the International Mesothelioma Interest Group (IMIG), a member of the steering committee for the British Lung Foundation mesothelioma research network, and co-author of the UK BTS, and European (ESMO, ERS) mesothelioma treatment guidelines.
Speaking on experimental therapies for mesothelioma
Prof. Fennell is an internationally recognized clinical investigator and translational researcher with a focus on mesothelioma, with over 100 peer-reviewed publications in journals including Nature, Lancet, and Journal of the National Cancer Institute. Specifically, Prof. Fennell’s research centers on translating novel precision medicine strategies from the lab to the clinic. He is currently leading the CRUK TraceRx/Darwin studies in lung cancer and BLF supported MEDUSA (mesothelioma) evolution studies. He has led several investigator-initiated trials from phase I through to phase III, and he is chief investigator for the CONFIRM, VIM and MiST trials in relapsed mesothelioma.